In this guide
When researching weight-loss medication, you may see tirzepatide, Zepbound and Mounjaro discussed together. The names are connected, but they describe different things.
Tirzepatide is the active ingredient in both Zepbound and Mounjaro. Zepbound and Mounjaro are branded prescription products with different approved uses. Tirzepatide names the drug substance; the brand names identify specific medicines containing it. 1, 2
Understanding that distinction makes it easier to read medication information and compare what each product is approved to treat.
What each name means
| Name | Meaning |
|---|---|
| Tirzepatide | The active ingredient in Zepbound and Mounjaro. It is an ingredient name, not a brand. |
| Zepbound | A branded tirzepatide medicine with approved weight-management and obstructive sleep apnea uses. |
| Mounjaro | A branded tirzepatide medicine with approved type 2 diabetes and cardiovascular-risk-reduction uses. |
| Compounded tirzepatide | A compounded preparation containing tirzepatide; it is distinct from the FDA-approved branded products. |
These distinctions come from the current US prescribing information and FDA’s information on compounded GLP-1 drugs. 1, 2, 3
The names are therefore not three competing active ingredients. Zepbound and Mounjaro both contain tirzepatide. The important differences include the product’s approved uses and the labeling that accompanies it.
What is Zepbound approved for?
Zepbound is approved, alongside a reduced-calorie diet and increased physical activity, for long-term weight reduction and maintenance in adults with obesity, or overweight with at least one weight-related condition. It is also approved for moderate to severe obstructive sleep apnea in adults with obesity. 1
An indication is a use covered by a medicine’s approved labeling. For a reader researching weight management, Zepbound’s indication explains why that brand name appears in weight-loss discussions. Its sleep apnea indication is a separate approved use with its own patient population.
What is Mounjaro approved for?
Mounjaro is approved alongside diet and exercise for blood-sugar control in people with type 2 diabetes aged 10 and older. Its current US label also covers reducing cardiovascular death, nonfatal heart attack or nonfatal stroke risk in adults with type 2 diabetes who are at high risk for those events. 2
This differs from Zepbound’s weight-management indication. Reading that both brands contain tirzepatide does not mean their approved uses are identical. When a discussion mentions Mounjaro and weight loss together, keep the product’s labeled indications separate from the broader conversation about its ingredient.
The labels describe the approved uses; a clinician considers whether a particular treatment fits an individual’s medical history and care goals.
How do pens and vials fit into the names?
A product name and a device name answer different questions. The product identifies the medicine; its presentation describes the supplied form or device.
Current US labels for both Zepbound and Mounjaro include single-dose pens, single-dose vials, multi-dose vials and single-patient-use KwikPens. A vial therefore does not, by itself, mean a medicine is compounded. 1, 2
This distinction also helps when reading instructions online. Information about a single-dose pen may not describe a multi-dose vial or a KwikPen, even within the same brand. Both labels call for training appropriate to the presentation supplied, including when it changes. 1, 2
How is compounded tirzepatide different?
Compounded tirzepatide is distinct from Zepbound and Mounjaro. FDA states that compounded drugs are not FDA approved and do not undergo its premarket review for safety, effectiveness or quality. The word compounded does not mean “FDA-approved generic Zepbound” or “FDA-approved generic Mounjaro.” 3
The ingredient name explains the connection, while the product distinction explains why the terms should not be used interchangeably. A branded product’s approved uses and instructions should not be presented as the approval or instructions for a compounded preparation.
Questions that make medication research clearer
As you read about treatment options or discuss them with a clinician, focus on three questions:
- Does this information describe an ingredient or a specific product? “Tirzepatide” is broader than either brand name.
- Which approved use is being discussed? Weight management, diabetes care and sleep apnea are different treatment contexts.
- Which form or device do the instructions describe? A medicine’s presentation matters when interpreting directions.
For personal treatment questions, ask a clinician how the intended use fits your health history. Understanding the names helps you follow that conversation; it does not provide instructions for switching products or selecting a dose.
Sources
- Zepbound US prescribing information, Eli Lilly and Company. Revised August 2026; checked October 12, 2026. Consult the product’s current Medication Guide and presentation-specific Instructions for Use alongside this prescribing information.
- Mounjaro US prescribing information, Eli Lilly and Company. Revised August 2026; checked October 12, 2026. Consult the product’s current Medication Guide and presentation-specific Instructions for Use alongside this prescribing information.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Checked October 12, 2026.